| 44.1456 0.901 (2.08%) | 10-09 15:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 57.57  |
1-year : | 62.78 |
| Resists | First : | 49.29 |
Second : | 53.75 |
| Pivot price | 45.57 |
|||
| Supports | First : | 42.06 | Second : | 35 |
| MAs | MA(5) : | 43.68 |
MA(20) : | 46.41 |
| MA(100) : | 48.81 |
MA(250) : | 43.08 |
|
| MACD | MACD : | -2 |
Signal : | -1.9 |
| %K %D | K(14,3) : | 15.2 |
D(3) : | 10.1 |
| RSI | RSI(14): 35.7 |
|||
| 52-week | High : | 56.18 | Low : | 28.24 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BBC ] has closed above bottom band by 30.5%. Bollinger Bands are 6.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 44.46 - 44.68 | 44.68 - 44.86 |
| Low: | 42.44 - 42.69 | 42.69 - 42.9 |
| Close: | 43.76 - 44.14 | 44.14 - 44.48 |
This exchange-traded fund (ETF) endeavors to match the capital appreciation and income generation of the LifeSci Biotechnology Clinical Trials Index, disregarding fees and expenses. The underlying index focuses on tracking the financial progress of a carefully chosen group of biotechnology firms engaged in clinical trials. It is important to note that, as of February 27, the fund's official name transitioned from Virtus LifeSci Biotech Clinical Trials ETF to Virtus Biotech Clinical Trials ETF.
Sat, 29 Aug 2026
Venture Into High-Volatility Corners of the Market With These 3 ETFs - MarketBeat
Mon, 27 Jul 2026
Innovative ETF Strategies That Are Paying Off This Summer - Yahoo Finance
Wed, 01 Jul 2026
June's Top ETFs: Biotech & China Semiconductors Surge - ETF Database
Tue, 30 Jun 2026
Biotech ETF (BBC) Touches a New 52-Week High - Zacks Investment Research
Tue, 23 Jun 2026
Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead? - TradingView
Wed, 17 Apr 2024
The 5 Best Biotech ETFs of 2024 - ETF.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|